Payment overview · 2025
General Payments
$416.34
22 reported records · 12 companies
Healthcare provider profile · identity verified
Michael Raymond Hess, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GRAFTON, WV · NPI 1750478269
Verified facts
What the public records show
CMS Open Payments records show Michael Raymond Hess, M.D. received $416.34 in general payments during 2025 across 22 reported records.
Amgen Inc. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Viibryd by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.22 | 21.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.34 | 15.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.01 | 10.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.61 | 9.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.53 | 8.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.01 | 7.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.65 | 6.9% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $24.24 | 5.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.41 | 5.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.09 | 5.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.80 | 3.3% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $1.43 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $416.34 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $90.22 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.27 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $43.01 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.61 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.53 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.01 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.65 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 256 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 241 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 238 | 66 |
| Losartan Potassium | Losartan Potassium | 214 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 204 | 54 |
| Lisinopril | Lisinopril | 200 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 56 |
| Atorvastatin Calcium | Atorvastatin Calcium | 173 | 48 |
| Metformin Hcl | Metformin Hcl | 139 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 41 |
| Omeprazole | Omeprazole | 131 | 38 |
| Furosemide | Furosemide | 126 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 40 |
| Montelukast Sodium | Montelukast Sodium | 123 | 29 |
| Potassium Chloride | Potassium Chloride | 109 | 31 |
| Tramadol Hcl | Tramadol Hcl | 108 | 22 |
| Simvastatin | Simvastatin | 92 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 25 |
| Clonazepam | Clonazepam | 80 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 21 |
| Eliquis | Apixaban | 76 | 18 |
| Alendronate Sodium | Alendronate Sodium | 75 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 67 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 31 |
| Glipizide | Glipizide | 64 | 22 |
| Allopurinol | Allopurinol | 63 | 17 |
| Prednisone | Prednisone | 61 | 28 |
| Sertraline Hcl | Sertraline Hcl | 60 | 18 |
| Trazodone Hcl | Trazodone Hcl | 60 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 12 |
| Synthroid | Levothyroxine Sodium | 48 | 13 |
| Valsartan | Valsartan | 48 | 12 |
| Famotidine | Famotidine | 45 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 19 |
| Lorazepam | Lorazepam | 44 | suppressed |
| Spironolactone | Spironolactone | 43 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Carvedilol | Carvedilol | 41 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Azithromycin | Azithromycin | 37 | 26 |
| Ezetimibe | Ezetimibe | 37 | 12 |
| Ozempic | Semaglutide | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 17 |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 11 |
| Meloxicam | Meloxicam | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 11 |
| Diazepam | Diazepam | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 27 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 14 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Nystatin | Nystatin | 18 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Humira(Cf) Pen | Adalimumab | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Pentasa | Mesalamine | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Viibryd | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $416.34 · 22 records | Amgen Inc. | Cologuard Collection Kit, EVENITY, JARDIANCE, Kerendia, LEQVIO, LINZESS, LifeVest, Ohtuvayre, Ozempic, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Veozah, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error